The new therapeutic approach is based on shutting down the viral hepatitis B genome located in the nucleus of infected liver cells. Upon infection of the liver cell, the viral…
What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly…
The innate immune system is the first line of defence after infection by viruses and other pathogens. Molecular patterns typical of pathogens – so-called…
Infections with the hepatitis B virus (HBV) are one of the major global health problems. More than 240 million people worldwide are chronically infected with…
Infections with the hepatitis B virus (HBV) are a global health problem. According to the World Health Organisation (WHO), more than 260 million people…
Vaccinations are the world's frontline defence against infectious diseases yet despite decades of interventions, unsafe injection practices continue to expose…